Glox Therapeutics secures £4.3m seed funding to combat AMR
The bacteriocin development programme will first target pseudomonas aeruginosa
Read More
Tag: bacteriocin development programme
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
